SEOM clinical guidelines for the treatment of small-cell lung cancer (SCLC) (2019)
Dómine Gómez, Manuel ![ORCID Identifier](/img/uab/orcid.ico)
(Hospital Universitario Fundación Jiménez Díaz)
Moran, T. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Isla, Dolores ![ORCID Identifier](/img/uab/orcid.ico)
(Hospital Clínico Universitario "Lozano Blesa" de Zaragoza)
Martí, J.L. (Hospital General Universitario de Alicante (Alacant, País Valencià))
Sullivan, Ivana ![ORCID Identifier](/img/uab/orcid.ico)
(Institut d'Investigació Biomèdica Sant Pau)
Provencio, M. (Hospital Universitario Puerta de Hierro Majadahonda (Madrid))
Olmedo, M.E. (Hospital Universitario Ramón y Cajal (Madrid))
Ponce, S. (Hospital 12 de Octubre (Madrid))
Blasco, A. (Centro Nacional de Investigaciones Oncológicas)
Cobo, M. (Hospital Regional Universitario de Málaga)
Universitat Autònoma de Barcelona
Date: |
2020 |
Abstract: |
Small-cell lung cancer (SCLC) accounts for 15% of lung cancers. Only one-third of patients are diagnosed at limited stage. The median survival remains to be around 15-20 months without significative changes in the strategies of treatment for many years. In stage I and IIA, the standard treatment is the surgery followed by adjuvant therapy with platinum-etoposide. In stage IIB-IIIC, the recommended treatment is early concurrent chemotherapy with platinum-etoposide plus thoracic radiotherapy followed by prophylactic cranial irradiation in patients without progression. However, in the extensive stage, significant advances have been observed adding immunotherapy to platinum-etoposide chemotherapy to obtain a significant increase in overall survival, constituting the new recommended standard of care. In the second-line treatment, topotecan remains as the standard treatment. Reinduction with platinum-etoposide is the recommended regimen in patients with sensitive relapse (≥ 3 months) and new drugs such as lurbinectedin and immunotherapy are new treatment options. New biomarkers and new clinical trials designed according to the new classification of SCLC subtypes defined by distinct gene expression profiles are necessary. |
Rights: |
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. ![Creative Commons](/img/licenses/by.ico) |
Language: |
Anglès |
Document: |
Article ; recerca ; Versió publicada |
Subject: |
Chemotherapy ;
Immunotherapy ;
Radiotherapy ;
SCLC |
Published in: |
Clinical & translational oncology, Vol. 22 Núm. 2 (january 2020) , p. 245-255, ISSN 1699-3055 |
DOI: 10.1007/s12094-020-02295-w
PMID: 32040815
The record appears in these collections:
Research literature >
UAB research groups literature >
Research Centres and Groups (research output) >
Health sciences and biosciences >
Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)Research literature >
UAB research groups literature >
Research Centres and Groups (research output) >
Health sciences and biosciences >
Institut de Recerca Sant PauArticles >
Research articlesArticles >
Published articles
Record created 2023-10-14, last modified 2024-06-15